Mesalazine (PENTASA®) in Ulcerative Colitis
NCT01517607 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 506
Last updated 2015-10-01
Summary
This non-interventional study examines whether the patient's level of information and the consideration of the patient's preference have a positive effect on the compliance and thus also on the therapeutic success.
Conditions
Interventions
- OTHER
-
Mesalazine
Patient's treated with oral Mesalazine
Sponsors & Collaborators
-
Ferring Arzneimittel GmbH
collaborator INDUSTRY -
Ferring Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Clinical Development Support · Ferring Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-02-29
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- Germany
Study Locations
More Related Trials
-
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
NCT01745770 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
NCT01257386 ·Status: COMPLETED ·Phase: PHASE3
-
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)
NCT02368743 ·Status: COMPLETED
-
Atorvastatin in Patients With Ulcerative Colitis
NCT05561062 ·Status: COMPLETED ·Phase: PHASE2
-
Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis
NCT03604536 ·Status: TERMINATED
-
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
NCT00737789 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
NCT01257399 ·Status: COMPLETED ·Phase: PHASE3
-
Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis
NCT01517594 ·Status: COMPLETED
-
Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine
NCT06525974 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
NCT01011322 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study With Pentasa in Patients With Active Crohn's Disease
NCT00862121 ·Status: TERMINATED ·Phase: PHASE3
-
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
NCT00064441 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
NCT06176560 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT00659802 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942 ·Status: ACTIVE_NOT_RECRUITING
-
Canadian Active & Maintenance Modified Pentasa Study
NCT00603733 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis
NCT00808977 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting Response to Standardized Pediatric Colitis Therapy
NCT01536535 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Cortiment® in Patients With Ulcerative Colitis
NCT02586259 ·Status: COMPLETED
-
Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis
NCT05567068 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Data Analysis in Crohn's Disease
NCT01363427 ·Status: COMPLETED
-
the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis
NCT05626166 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
NCT02958865 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925 ·Status: RECRUITING
-
Pentoxifylline in Patients With Ulcerative Colitis
NCT07349472 ·Status: RECRUITING ·Phase: PHASE2